Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,021 Cr
P/E Ratio
23.42
P/B Ratio
2.68
Industry P/E
36.27
Debt to Equity
0
ROE
11.21 %
ROCE
16.35 %
Div. Yield
3.05 %
Book Value
305.66
EPS
34.94
CFO
₹27.40 Cr
EBITDA
₹245.97 Cr
Net Profit
₹680.56 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Novartis India
| -11.03 | -2.28 | -9.58 | -20.25 | 8.40 | 6.65 | 3.40 |
|
BSE Healthcare
| -7.27 | -1.01 | -0.76 | 19.87 | 19.29 | 22.12 | 9.77 |
|
BSE Small Cap
| -12.38 | 0.32 | -4.19 | 2.45 | 17.96 | 35.18 | 15.87 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Novartis India
| 18.60 | 14.56 | -12.94 | 12.47 | 2.23 | -7.96 | 10.26 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 735.15 | 6,661.19 | 26.72 | 13.8 | |
| 1,069.80 | 8,742.78 | 72.03 | 12.96 | |
| 452.55 | 10,967.83 | 22.89 | 14.4 | |
| 884.20 | 5,068.41 | 39.78 | 14.76 |
3 min read•By Ashish Jain
Novartis India Limited operates as a healthcare company in India. It offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and... Myfortic brands; and neurosciences products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG. Read more
Incorporated
1947
Chairman
Christopher Snook
Managing Director
--
Group
Novartis India - MNC
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Novartis India Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Novartis India Ltd stood at ₹ 891 Cr as on 31-Dec-24
The share price of Novartis India Ltd is ₹818.35 (BSE) and ₹672.25 (NSE) as of 25-Apr-2025 IST. Novartis India Ltd has given a return of 8.4% in the last 3 years.
Novartis India Ltd has a market capitalisation of ₹ 2,021 Cr as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Novartis India Ltd is 2.68 times as on 25-Apr-2025, a 26% discount to its peers’ median range of 3.63 times.
The P/E ratio of Novartis India Ltd is 23.42 times as on 25-Apr-2025, a 35% discount to its peers’ median range of 36.27 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Novartis India Ltd and enter the required number of quantities and click on buy to purchase the shares of Novartis India Ltd.
Novartis India Limited operates as a healthcare company in India. It offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands; and neurosciences products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.
The promoter of Novartis India Ltd is NOVARTIS AG. NOVARTIS AG owns 70.68 per cent of the total equity. The chairman of the company is Christopher Snook ..
There is no promoter pledging in Novartis India Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
10,968
|
|
|
8,743
|
|
|
6,661
|
|
|
5,068
|
| Novartis India Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
11.71
|
|
Operating margin(%)
|
21.76
|
|
Net Margin(%)
|
21.83
|
|
Dividend yield(%)
|
3.05
|
Yes, TTM profit after tax of Novartis India Ltd was ₹86 Cr.
₹-6.95
(
